1. FDA. FDA approves Praluent to treat certain patients with high cholesterol [media release]. 24 July 2015. www.fda.gov .
2. European Medicines Agency. Praluent (alirocumab) - summary of opinion. 2015. http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/003882/WC500190416.pdf . Accessed 1 Sept 2015.
3. Sanofi-aventis, Regeneron Pharmaceuticals Inc. Sanofi-aventis initiates a major global collaboration with Regeneron to develop and commercialize fully-human therapeutic antibodies and plans to increase its stake in Regeneron to approximately 19 % [media release]. 3 Dec 2007. http://en.sanofi.com .
4. Sanofi-aventis. Sanofi-aventis and Regeneron expand strategic antibody collaboration [media release]. 12 Nov 2009. http://en.sanofi.com .
5. Sanofi-aventis, Regeneron Pharmaceuticals Inc. Sanofi and Regeneron announce collaboration with American College of Cardiology for PCSK9 inhibitor clinical program [media release]. 19 Dec 2013. http://investor.regeneron.com .